PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit www.peptidream.com.
Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 130,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.9 trillion yen (US$35 billion) for the fiscal year ended March 31, 2020. For more information, please see www.fujitsu.com.
Mizuho Capital is an integral part of the Japan-based Mizuho Financial Group, Inc.(TSE:8411), one of the largest financial institutions in the world, offering comprehensive financial and strategic services including private banking and venture capital through its subsidiaries. The group has over 900 offices and 60,000 employees worldwide in nearly 40 countries throughout the Americas, EMEA, and Asia. As of December 31, 2019, its total assets were $1.8 trillion. Learn more about Mizuho Financial Group at www.mizuho-fg.com.
Takenaka Corporation is one of the largest architecture, engineering, and construction firms in Japan. With annual sales of $12 billion, 20 overseas offices, the largest construction R&D laboratory in the world and over 2,000 architects in the design department, Takenaka offers comprehensive services worldwide across the entire spectrum of space creation from site location and planning to design and construction as well as postcompletion services such as building maintenance. For more information, please see https://www.takenaka.co.jp/takenaka_e/.
KISHIDA CHEMICAL was established in 1941, as a comprehensive manufacturer of reagents, we have expanded not only general reagent business, but also battery material business, drug discovery support business and life science business. And we have continuously grown as a fast and flexible company that can respond to a wide range of our customers' needs. Based on the slogan “All for Our Customer’s Research and Development”, we will continue to contribute to our customers' success in research and development through “Reliable Technology and Reliable Quality”. For more information, please visit our website https://www.kishida.co.jp/english/
Press ContactsMie Yamazaki - IR & Public Affairs
Press ContactsPublic and Investor Relations Division
Press ContactsCorporate Planning Department
Phone: +81 (0)3-3596-1270
Company:Mizuho Capital Co., Ltd.
Press ContactsPublic Relations Department
Phone: +81 (0)3-6810-5140
All company or product names mentioned herein are trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.
Date: 12 November, 2020
City: Tokyo and Kawasaki, Japan
Company: PeptiDream Inc. ,Fujitsu Limited ,Mizuho Financial Group, Inc. ,Mizuho Capital Co., Ltd. ,Takenaka Corporation ,KISHIDA CHEMICAL CO., LTD.
Share this page